Mining the Hippo signalling pathway for novel anti-cancer therapeutics

Candidates are invited to join the Kadri Lab, where our research focuses on developing innovative chemical approaches for discovering novel therapeutics to address unmet global health needs. Our research is multidisciplinary, spanning the fields of chemical biology, medicinal chemistry, computer-aided drug design, high-throughput screening, protein crystallography, and biochemistry. 

This project will build upon our recent exciting findings in deciphering the important role of the Hippo signalling pathway and its implications in various health diseases, particularly cancer. The aim is to capitalize on the group's expertise in the use of the powerful PROteolysis TArgeting Chimera (PROTAC) technology to develop novel small molecule modulators of this pathway. 

The candidate will have access to state-of-the-art laboratories, facilities, and equipment available at Kingston University London. This multidisciplinary drug discovery project will provide an excellent opportunity to receive high-quality training in a range of techniques at the interface of chemistry and biology, including computer-assisted drug design, chemical synthesis, targeted protein degradation, cell culture, and biochemical-based techniques for the biological evaluation of the synthesized compounds.